Home » Stocks » Anavex Life Sciences

Anavex Life Sciences Corp. (AVXL)

Stock Price: $4.80 USD 0.38 (8.60%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $4.85 +0.05 (1.04%) Aug 4, 7:58 PM

Stock Price Chart

Key Info

Market Cap 288.40M
Revenue (ttm) n/a
Net Income (ttm) -24.78M
Shares Out 60.08M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $4.80
Previous Close $4.42
Change ($) 0.38
Change (%) 8.60%
Day's Open 4.39
Day's Range 4.36 - 4.88
Day's Volume 555,197
52-Week Range 2.20 - 6.31

More Stats

Market Cap 288.40M
Enterprise Value 261.83M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 60.08M
Float 56.37M
EPS (basic) -0.45
EPS (diluted) -0.48
FCF / Share -0.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.39M
Short Ratio 6.94
Short % of Float 11.95%
Beta 1.51
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.83
Revenue n/a
Operating Income -28.97M
Net Income -24.78M
Free Cash Flow -21.02M
Net Cash 26.56M
Net Cash / Share 0.44
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -63.06%
ROE -133.21%
ROIC 1,127.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(150.00% upside)
Current: $4.80
Target: 12.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-29.11-19.33-15.68-15.59-7.11-2.97-2.14-4.32-6.17-5.64
Net Income-26.29-17.25-13.46-14.74-12.11-9.97-3.70-8.30-7.31-8.78
Shares Outstanding48.9144.6640.8435.1518.589.807.987.046.295.36
Earnings Per Share-0.54-0.39-0.33-0.42-0.65-1.02-0.48-1.16-1.16-1.64
Operating Cash Flow-18.53-12.58-9.02-9.24-4.23-2.66-0.78-1.69-3.80-4.59
Capital Expenditures----------
Free Cash Flow-18.53-12.58-9.02-9.24-4.23-2.66-0.78-1.69-3.80-4.60
Cash & Equivalents22.1922.9827.499.2415.297.260.350.010.130.26
Total Debt----
Net Cash / Debt22.1922.9827.499.2415.217.070.13-0.29-0.73-2.23
Book Value20.2922.3224.256.3112.810.19-2.46-2.88-1.14-2.96
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anavex Life Sciences Corp.
Country United States
Employees 16
CEO Christopher U. Missling

Stock Information

Ticker Symbol AVXL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AVXL


Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.